Potential efficacy of caffeine ingestion on balance and mobility in patients with multiple sclerosis: Preliminary evidence from a single-arm pilot clinical trial.
多発性硬化症患者におけるカフェイン摂取の平衡機能と移動能への潜在的効果:単群パイロット臨床試験からの予備的エビデンス (機械翻訳の邦題)
記録の確認項目
- 研究デザイン
- その他の原著論文
- 対象
- ヒト
- 出版年
- 2024
- 出典
- doi.org
- 抄録の表示
- 表示あり
- 出版状態
- 有効な記録
- 状態確認日
- 2026/08/17
- 収集日
- 2026/08/03
- 鮮度
- 確認期限内
- 確認段階
- 自動処理
- 記録状態
- 公開
日本語要約(機械生成)
多発性硬化症(MS)患者におけるカフェインの平衡機能、移動能、健康関連QOLへの効果を検討する単群パイロット臨床試験を実施した。2週間のプラセボ導入後、12週間カフェイン200mg/日を投与し、MSWS-12、BBS、TUG、MSIS-29、PGICを経時的に評価した。30名のMS患者(平均年齢38.89歳、女性76.7%)を対象とした結果、カフェイン摂取によりBBSとTUGが有意に改善し、MSIS-29も介入2週間後に有意に改善した。MSWS-12とPGICは有意な変化を示さなかった。性別と時間の交互作用がMSWS-12とPGICで認められ、年齢の影響はBBSで時間経過とともに増大した。カフェインはMS患者の平衡機能、移動能、QOLを向上させる可能性が示唆された。
この要約は公開抄録のみを根拠にAIが機械的に生成したものです。正確な内容は原文を確認してください。
抄録
Objectives: Caffeine's potential benefits on multiple sclerosis (MS), as well as on the ambulatory performance of non-MS populations, prompted us to evaluate its potential effects on balance, mobility, and health-related quality of life (HR-QoL) of persons with MS (PwMS).Methods: This single-arm pilot clinical trial consisted of a 2-week placebo run-in and a 12-week caffeine treatment (200 mg/day) stage. The changes in outcome measures during the study period (weeks 0, 2, 4, 8, and 12) were evaluated using the Generalized Estimation Equation (GEE). The outcome measures were the 12-item Multiple Sclerosis Walking Scale (MSWS-12) for self-reported ambulatory disability, Berg Balance Scale (BBS) for static and dynamic balance, Timed Up and Go (TUG) for dynamic balance and functional mobility, Multiple Sclerosis Impact Scale (MSIS-29) for patient's perspective on MS-related QoL (MS-QoL), and Patients' Global Impression of Change (PGIC) for subjective assessment of treatment efficacy. GEE was also used to evaluate age and sex effect on the outcome measures over time. (Iranian Registry of Clinical Trials, IRCT2017012332142N1).Results: Thirty PwMS were included (age: 38.89 ± 9.85, female: 76.7%). Daily caffeine consumption significantly improved the objective measures of balance and functional mobility (BBS; P-value<0.001, and TUG; P-value = 0.002) at each study time point, and the subjective measure of MS-related QoL (MSIS-29; P-value = 0.005) two weeks after the intervention. Subjective measures of ambulatory disability (MSWS-12) and treatment efficacy (PGIC) did not significantly change. The effect of age and sex on the outcome measures were also assessed; significant sex-time interaction effects were found for MSWS-12 (P-value = 0.001) and PGIC (P-value<0.001). The impact of age on BBS scores increased as time progressed (P-value = 0.006).Conclusions: Caffeine may enhance balance, functional mobility, and QoL in PwMS. Being male was associated with a sharper increase in self-reported ambulatory disability over time. The effects of aging on balance get more pronounced over time.Trial registration: This study was registered with the Iranian Registry of Clinical Trials (Registration number: IRCT2017012332142N1), a Primary Registry in the WHO Registry Network.
MeSH
DOI 10.1371/journal.pone.0297235
PMID 38349929
原文・出典を見る →